TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9346224
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2) with carboplatin (AUC 7) alternating with cisplatin (75 mg/m2)
Study: 2637911
Drug: PT-01 (controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT-01 (controlled-release insert containing ofloxacin)
Study: 25423960
Drug: S-1 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 adjuvant chemotherapy (S-1(+)-group) administered after 2003
Study: 25423960
Drug: No S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: No S-1 adjuvant chemotherapy (S-1(-)-group) before 2003
Study: 23530078
Drug: Combination artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combination artesunate (AS)/amodiaquine (AQ) therapy
Study: 15499517
Drug: Liposome eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome eye spray (TEARS AGAIN, Optima Pharmaceutical GmbH, Germany)
Study: 15499517
Drug: Liposome eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome eye spray (TEARS AGAIN)
Study: 11755562
Drug: Atenolol therapy
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol therapy for high cardiac output (greater than 7.4 L/minute)
Study: 1720486
Drug: isradipine 1.25-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: isradipine 1.25-2.5 mg twice daily
Study: 1720486
Drug: metoprolol 50-100
Normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoprolol 50-100 mg twice daily
Study: 6817845
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate treatment for 6 months
Study: 6817845
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C treatment for 6 months
Study: 29962032
Drug: G‐CSF with
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF with EPO (Group A; n = 30)
Study: 29962032
Drug: G‐CSF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF and placebo (Group B; n = 30)
Study: 26380359
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy (CBGT), 12 sessions
Study: 23585303
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of biapenem 0.15 g
Study: 23585303
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of biapenem 0.3 g
Study: 23585303
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of biapenem 0.6 g
Study: 23585303
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of biapenem 0.3 g
Study: 20615931
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg glycine
Study: 19820270
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 mg with omeprazole (40 mg/day for 14 days)
Study: 19820270
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 mg without omeprazole
Study: 19820270
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended-release (MAS XR) 20 mg with omeprazole (40 mg/day for 14 days)
Study: 19820270
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended-release (MAS XR) 20 mg without omeprazole
Study: 11231932
Drug: Racecadotril (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril (1.5 mg/kg orally 3 times daily)
Study: 9888613
Drug: Zolmitriptan (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (5, 10, 15, or 20 mg)
Study: 835924
Drug: Pectin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin (10 g added to marmalade)
Study: 31895459
Drug: New cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cardiovascular drugs (lipid-modifying, antithrombotic, anti-inflammatory, and antidiabetic drugs)
Study: 31895459
Drug: New cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cardiovascular drugs
Study: 25773480
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine at doses of 0.1 mg/kg, 0.2 mg/kg, and 0.3 mg/kg
Study: 21118280
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg and 90 mg
Study: 18810712
Drug: Oral DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DHEA (9 subjects)
Study: 17302022
Drug: High-energy extracorporeal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy extracorporeal shock wave treatment (ESWT)
Study: 9237964
Drug: 10 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/d olestra
Study: 9237964
Drug: 10 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/d triglyceride
Study: 9237964
Drug: 0, 8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0, 8, 20 or 32 g olestra in potato chips
Study: 8257487
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg daily)
Study: 8257487
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg daily)
Study: 8257487
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg) plus Minocycline (100 mg daily)
Study: 7798371
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic medication regimen
Study: 29246277
Drug: β-Alanine (BA)
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-Alanine (BA) supplementation (6 g·d‐1 for 28 days)
Study: 26386159
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide implant treatment
Study: 24835860
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg paracetamol and 600 mg ibuprofen administered one hour before the procedure
Study: 24835860
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication administered
Study: 19641359
Drug: Naftopidil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil (50 mg/day)
Study: 9832296
Drug: Topical nimesulide
Normalized name: nimesulide Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nimesulide gel (10 mg)
Study: 9832296
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac gel (10 mg)
Study: 9832296
Drug: Topical piroxicam
Normalized name: piroxicam Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical piroxicam gel (10 mg)
Study: 792844
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antilymphocyte globulin (ALG) and thoracic duct drainage (TDD)
Study: 30181363
Drug: Blind tracheal
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind tracheal suctioning plus cleaning maneuver every 8 hours (treatment group)
Study: 28011389
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of long‐acting naltrexone in prison, followed by 6 monthly injections post‐release at a community opioid treatment program
Study: 28011389
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of long‐acting naltrexone in prison followed by 6 monthly injections post‐release at the patient's place of residence utilizing mobile medical treatment
Study: 25992914
Drug: Triple therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy: MTX+sulfasalazine (SSZ)+hydroxychloroquine (HCQ)
Study: 25992914
Drug: Anti-tumour necrosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumour necrosis factor (anti-TNF) therapy: MTX+infliximab
Study: 25992914
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (anti-TNF therapy)
Study: 25992914
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (triple therapy)
Study: 23234418
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (IVGTT)
Study: 21792622
Drug: Upper‐limb robotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper‐limb robotic therapy
Study: 19458107
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg with soy extract (Genistein Soy Complex 1000 mg, twice daily for 14 days)
Study: 19458107
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg without soy extract
Study: 15459410
Drug: Erythromycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (4 times daily for 10 days)
Study: 11403509
Drug: Colesevelam 2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 2.3 g at dinner
Study: 11403509
Drug: Lovastatin 10
Normalized name: lovastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 10 mg at dinner
Study: 11403509
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of colesevelam and lovastatin dosed together
Study: 11403509
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of colesevelam and lovastatin dosed apart
Study: 9714974
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream (2%)
Study: 7529391
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml of Hespan to 16 ml of blood
Study: 7529391
Drug: Donor cells,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor cells, anti‐granulocyte antibody labelling or HIG
Study: 2970744
Drug: Reaferon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reaferon (1 X 10(6) I. U.) administered orally, twice a week for two months.
Study: 2970744
Drug: Placebo (diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (diluent alone) administered twice a week for two months.
Study: 31823620
Drug: Atomoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (40 mg/d)
Study: 18006539
Drug: Anti-tumour necrosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumour necrosis factor (TNF) therapy
Study: 18006539
Drug: CRP >/=40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP >/=40 mg/litre
Study: 8447521
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (300 and 400 micrograms/kg)
Study: 31282129
Drug: UFR-guided hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFR-guided hydration with normal saline plus low-dose furosemide controlled by the RenalGuard system to maintain a high urine flow rate (>300 mL/hr)
Study: 31282129
Drug: LVEDP-guided hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVEDP-guided hydration with normal saline adjusted according to LVEDP levels (5 mL kg-1 hr-1 for LVEDP ≤12 mmHg, 3 mL kg-1 hr-1 for LVEDP 13-18 mmHg, and 1.5 mL kg-1 hr-1 for LVEDP >18 mmHg)
Study: 27264220
Drug: Escitalopram (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (5-20 mg qd)
Study: 22585691
Drug: Adjuvant radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiochemotherapy (Fluorouracil and leucovorin before, during, and after radiotherapy; Radiotherapy dose of 45 Gy)
Study: 20133510
Drug: Ketoprofen patch
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen patch (20 mg, once daily for 2 weeks)
Study: 20133510
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (once daily for 2 weeks)
Study: 31077671
Drug: Ketoprofen patch
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen patch
Study: 20133510
Drug: Ketoprofen patch
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen patch and Placebo patch
Study: 6338610
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (metronidazole and cephradine) given preoperatively
Study: 6338610
Drug: Antibiotics given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics given at operation only upon finding perforation, gangrene or pus formation
Study: 24867298
Drug: Pregabalin CR
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin CR (330-495 mg/day)
Study: 23092336
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) - ten sessions
Study: 20175941
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 300 mg/d
Study: 20175941
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 150 mg/d
Study: 15613570
Drug: Etamsylate 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamsylate 12.5 mg/kg six hourly from within one hour of delivery for four days
Study: 12440799
Drug: Increased intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased intensity of therapy (67% more therapy per week)
Study: 12440799
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy intensity)
Study: 10530655
Drug: IV EtOH
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV EtOH (10% solution administered over 30 minutes)
Study: 10530655
Drug: PO EtOH
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO EtOH (20% solution in juice administered over 10 minutes)
Study: 7548380
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment started during operation (Cefuroxime and Tinidazole)
Study: 7548380
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment started before operation (Cefuroxime and Tinidazole)
Study: 1971590
Drug: Xamoterol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 0.2 mg kg‐1 i.v.
Study: 28575331
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (GDT) guided by oesophageal Doppler monitoring
Study: 19622153
Drug: Urodynamic evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urodynamic evaluation followed by operative therapy
Study: 19622153
Drug: Urodynamic evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urodynamic evaluation followed by individually tailored therapy
Study: 15242431
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of an ordinary paracetamol tablet
Study: 15242431
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of an ordinary paracetamol tablet
Study: 15242431
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of a bicarbonate paracetamol tablet
Study: 15242431
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of a bicarbonate paracetamol tablet
Study: 15242431
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenously of prodrug propacetamol
Study: 7634866
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone (2‐mg/kg bolus followed by 0.0078 mg/kg/min)
Study: 7634866
Drug: Oral propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone (600 mg orally single dose)
Study: 21854285
Drug: Screening, brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening, brief intervention, and referral to treatment model in medical EDs
Study: 20146894
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg loading dose followed by 200 mg twice daily)
Study: 20146894
Drug: Non-selective NSAIDs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective NSAIDs (standard doses)
Study: 11431647
Drug: Intravaginal Crinone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal Crinone, 90 mg/day (n=51)
Study: 11431647
Drug: Intramuscular Prontogest,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Prontogest, 50 mg/day (n=48)
Study: 11431647
Drug: Intravaginal Crinone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal Crinone, 90 mg/day
Study: 11431647
Drug: Intramuscular Prontogest,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Prontogest, 50 mg/day
Study: 28799823
Drug: 2'-O-Methoxyethyl-modified antisense
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2'-O-Methoxyethyl-modified antisense oligonucleotides (ASOs) administered at doses ranging from 50 to 450 mg via subcutaneous injection and up to 600 mg via intravenous infusion
Study: 19823051
Drug: Bivalent HPV
Normalized name: HPV, bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent HPV vaccine (Cervarix)
Study: 19823051
Drug: Bivalent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent and Quadrivalent HPV vaccines
Study: 9694550
Drug: Pravastatin (36.64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (36.64 mg daily for 3 years)
Study: 2772858
Drug: Phosphate buffered
Normalized name: Phosphate Buffered Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline (control solution)
Study: 17374
Drug: Metyrosine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrosine (administered for three weeks)
Study: 31387121
Drug: Menaquinone-7 (MK-7)
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-7 (MK-7) 360 µg/d for 6 months
Study: 7541310
Drug: Hydromorphone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (1 mg IV)
Study: 9649160
Drug: MVP (mitomycin‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVP (mitomycin‐C 6 mg m(‐2) on day 1, vindesine 3 mg m(‐2) on days 1 and 15, and cisplatin 80 mg m(‐2) on day 1 every 28 days)
Study: 9649160
Drug: PIN (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIN (cisplatin 80 mg m(‐2) day 1, ifosfamide 3 g m(‐2) day 1 and vinorelbine 25 mg m(‐2) day 1 and 8 every 21 days)
Study: 9649160
Drug: CaN (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaN (carboplatin 350 mg m(‐2) day 1 and vinorelbine 25 mg m(‐2) days 1 and 8 every 28 days)
Study: 7913675
Drug: Bivariate group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivariate group sequential design
Study: 1089678
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg GnRH/m2 iv in children
Study: 1089678
Drug: 1, 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 10, 25, and 100 μg GnRH/m2 iv in adults
Study: 1089678
Drug: GnRH iv
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH iv at 10 μg/m2 in children
Study: 31314206
Drug: Sweetened beverages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweetened beverages consumption (≥500 ml daily)
Study: 27542378
Drug: Multimedia self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimedia self-management intervention for lung surgery preparation
Study: 21787456
Drug: Barley porridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barley porridge with 16 g/100 g fibre content
Study: 21787456
Drug: Barley porridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barley porridge with 10 g/100 g fibre content
Study: 20530281
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and cisplatin (DP) chemotherapy with concurrent thoracic radiotherapy (TRT)
Study: 20530281
Drug: Mitomycin, vindesine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin, vindesine, and cisplatin (MVP) chemotherapy with concurrent TRT
Study: 10022628
Drug: Omeprazole-infusion
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-infusion
Study: 10022628
Drug: Ranitidine-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine-infusion
Study: 10022628
Drug: Omeprazole-injection
Normalized name: omeprazole Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole-injection
Study: 10022628
Drug: Ranitidine-injection
Normalized name: ranitidine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine-injection
Study: 21269302
Drug: Centrifugal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrifugal blood pumps (e.g., Rotaflow, Bio-Medicus)
Study: 21269302
Drug: Roller pumps
Normalized name: mumps virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roller pumps (e.g., Roller, Avecor, Sarns)
Study: 19675446
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 units subcutaneous on postoperative days 1 and 7)
Study: 15170918
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone pulse therapy (MPPT) - 1000 mg IV for 3 alternate days, mean interval of 76 days for one year.
Study: 15170918
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (OMP) - continuous therapy.
Study: 9663183
Drug: Intravenous dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dobutamine administered over a 24‐hour period every 2 to 3 weeks for 6 months.